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ABSTRACT. The chemical structure of 99mTc-GSH has been estabilished using the 99Tc isotope.
Labeling of glutathione with technetium in the presence of stanous chloride gave a high yield
result. In a comparative study between 99Tc and 99mTc glutathione, the Tc-GSH complex obtained
was purified and characterized by uv, visible spectroscopy, HPLC, Biogel chromatography, mass
and NMR spectroscopy. Stoichiometric analysis showed a 2 molar ratio of GSH/Tc for the
reaction. The molecular mass assessed by mass spectroscopy was 727 Da corresponding to an
oxo(bis) glutathione technetate. NMR studies demonstrated that each glutathione molecule was
coordinated to technetium via cysteinyl sulfur and nitrogen atoms. The biodistribution of the
complex was studied in normal rats. Blood clearance was rapid during the first hour involving a
biexponential curve tl/2 (1) 50 min, tl/2 (2) 400 min ). No radioactive accumulation was found in
any specific organ except kidney and bladder. All the activity excreted was found unchanged in
urine. In conclusion, Tc-GSH displayed an anionic dimer form as GSH-Tc-GSH. We assume that the
complex is a tetradentate (2N,2S) complex containing a pentavalent technetium coordinated by two
thiol and nitrogen atoms of both GSH ligands, and an apical oxo group.
INTRODUCTION
During the recent years increasing fundamental research about the structure of Tc
radiopharmaceuticals has been done using the long-lived 99Tc isotope (tl/2 2,13.105 yr). When
using 99Tc, one must bear in mind that the complex formations of 99Tc and 99mTc may be different,
resulting from the different concentration ranges used for the two isotopes(I,2) Several
investigators (3-7) have used 99mTc-labeled sulfhydryl containing aminoacids, carbonic acids and
heterocyclic compounds as a new approach in radiopharmaceutical design. It was demonstrated
that small molecular weight complexes of 99mTc with fast renal clearance or biliary excretion and no
significant uptake by any other organs showed sufficient accumulation in tumors for early
scintigraphic visualization (8-10). The renal route of excretion is an advantage over the biliary one,
especially for the identification of abdominal lesions (9,11). This point was also emphasized by
Fischman(1 1) with the use of chemotactic peptides. Peptides of low molecular weight labeled with
99mTc could be a better alternative because of their faster blood clearance and excretion mainly via
the kidney. Detailed structural information concerning Tc-radiopharmaceuticals is now available for
Tc-AHBDP (12), Tc-glucoheptonate (13) and oxotechnetium compounds (14). Glutathione /-
glutamyl cysteinyl glycine was chosen as a model compound because of the critical fonctions it
carried in humans (15). Due to its a small molecular weight, it was expected to better penetrate
injured capillaries in inflammatory lesions (16), breast cancer (17), head and neck tumors(18).
More detailed structural information about the radiopharmaceuticals in use today would greatly
facilitate the prediction of the in vivo stability and target-organ distribution. For this reason the study
of the Tc-GSH chemical structure and its biodistribution in rats were undertaken.
MATERIAL AND METHODS
Glutathione (reduced form), SnCI2, and buffer products were purchased from Sigma Aldrich.
Na99mTcO4 was eluted from a commercial 99Mo/gemTc generator (Cis Biolnternational). NH499TcO4
was obtained from Dupont-NEN laboratories.
Labeling reaction of the Tc-GSH complex was performed with 20 mg of glutathione dissolved in 2 ml
phosphate buffer while stirring and 0,3 ml of SnCI2.2H20 (1 mg/ml of HCI 0,05N) was added. The
mixture was stirred for a few minutes and filtered. 2 ml of pertechnetate were added and the mixture
was shaken for few seconds and left to react for 15 min at room temperature.
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The radiochemical purity of the Tc-GSH complex was assessed by ITLC using a
CHROMELUC Nu-102 radiochromatogram (Numelec) with silica-gel plates and two solvents
Butanone and NaCI.
Electrophoretic experiments of the Tc-GSH complex were performed on cellulose acetate
strips in phosphate buffer (0.05M, pH 7). 5 IJI of each solution were placed at midpoint of the band
and 200V was applied for lh at room temperature. After drying, each strip was cut into equal lenght
and the activity counted with a 13 counter (Beckman, LS 6000SC) for the 99Tc-GSH complex and y
counter (Wallac, LKB1261 ).
Ultraviolet and visible electron spectra of the Tc-GSH complex were recorded between 90
and 850 nm on a HEWLETT PACKARD 8452 spectrophotometer using closed 10-mm Supracil
quartz cuvettes.
Infrared spectra of the Tc-GSH complex were recorded from 600-4000 cm-1. Spectra were
performed on solid samples prepared as KBr pellets.
An analytical study of the 99mTc-GSH complex was determined by gradient HPLC (C-18
reversed phase uptisphere 5tJm UP50DB-25K, Interchim) using a flow rate of ml/mn equiped with
a UV-Vis detector and gamma-counting system (Nal crystal coupled to two channel analysers and
integrated by an Ezchrom software program (Merck). The complex (201) was eluted from the HPLC
column with a gradient medium of (A) 0,05M phosphate buffer pH 7 and (B) 30% ethanol in (A).
Gel chromatography of the Tc-GSH complex was performed on biogel P2 columns (Biorad)
with the technique introduced by Persson (19). The biogel P2 was used to separate and identify
smaller molecular weight compounds. The various samples were eluted with PBS (pH 7) and the
column was calibrated for different molecular weight ranges.
NMR analysis of the GSH and the Tc-GSH complex were obtained at 20C with a Varian NMR
spectrometer at 500MHz.
Fast atom bombardement mass spectroscopy (FAB+ -MS) of the Tc-GSH complex were
recorded with a MAT 95 spectrometer by mixing #1 sample with 5 1 glycerol and bombardement
with caesium atoms of low energy of about 150 eV at room temperature.
Blood clearance of 99mTc-GSH complex was studied in male sprague dawley rats (150-200g).
100 I1 of 99mTc-GSH were injected i.v. and blood samples drawn from a femoral vein at 5 min, 2h,
4h, 6h and 24h. The samples were counted in a gamma-counter. The means of percentage
injected dose were plotted with the course of time.
The in vivo distribution studies were performed in male sprague dawley rats (150-200g) by
injecting into the femoral vein 100 ml of 99mTc-GSH. Five rats were studied for each data point. The
rats were killed and dissected at lh, 6h postinjection. All the organs were removed, samples of
blood and urine were also obtained. The organ samples were weighted and counted in a gamma-
counter Wallac, LKB1261 )).
RESULTS
The Tc-GSH complex displayed a negative charge on paper electrophoresis. Instant thin
layer chromatography analysis results are summarized in table I. In general, free pertechnetate
moved to the solvent front whereas reduced 99mTc and bound 99mTc-R (R-Tc) remained at the spot
of origin in the butanone solvent. In the saline solvent, reduced 99mTc stayed at the origin whereas
the free pertechnetate and R-Tc moved with the solvent front. The labeling yield of 99mTc-GSH
detected by paper and thin layer chromatography was over 95%.The UV visible spectra of Tc-GSH
complex showed an absorbance band at 385 nm (fig.l). Glutathione alone and glutathione-Sn did
not absorb at 385 nm. The 99Tc-GSH complex was stable for more one week at room temperature.
The stoechiometry for the reaction of Tc with glutathione determined at partial molar ratios at
different glutathione concentrations (Sn/Tc/GSH 1/1/X, X 0-10) indicated the existence of two
GSH coordinated with one Tc ion (fig. 2).
Table Thin layer chromatography of 99Tc and 99mTc-GSH complex
Compound rf (NaCI) rf (Butanone)
99mTc04"
99TCO4" 99mTc-GSH 0
99Tc-GSH 0
The IR spectrum of the Tc-GSH complex showed the absence of the 2540 cm1 band and
the presence of the vibration band of the TC=O core (931 cml).
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Table II Proton NMR spectroscopic data of GSH and 99Tc-GSH complex
Compound cys cys gly glu glu glu
5(CaH2) 5(CBH2) 5(CaH2) 5(CaH2) i(CBH2) 5(CvH2)
GSH 3,794 2,917 3,943 4,539 2,122 2,507
3,807 2,929 3,953 4,550 2,137 2,521
3,820 2,936 2,150 2,537
2,165 2,552
Tc-GSH 3,767 2,956 3,791 4,550 2,158 2,558
3,779 2,971 3,813 4,563 2,170 2,573
2,185 2,583
5: ppm 2,199 2,597
The NMR spectrum of the GSH and the Tc-GSH complex demonstrated the disappearance
of fine structure of the signal (fig. 3). The proton signal (table II) indicated, in particular, that protons
bound to cysteinyl (z and 13 carbons appeared to be altered.
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Figure 3 1H NMR spectra of GSH (A) and 99Tc-GSH complex (B) at 500 MHz, 20C
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The 99Tc-GSH complex, analyzed by fast atom bombardement mass spectroscopy, showed a
molecular mass between 683 Da and 726 Da. This mass corresponded to a GSH-Tc-GSH chelate
complex. This complex containing a tetra or a pentavalent technetium coordinated by two thiol and
nitrogen atoms of two GSH ligand and an apical oxo group (fig. 4).
HPLC radiochromatograms of the 99mTc-GSH complex exhibit a single peak with a retention
time of 12 rnin, the retention time of free 99mTcO4" being equal to 6 min.
The radiochromatogram of the 99mTc-GSH obtained by analysis on the biogel P2 column
demonstrated that all the radioactivity was present in a single peak with an elution volume of 16 ml.
Analysis of free 99mTcO4" showed a single peak with an elution volume equal to 26 ml, (fig.5).
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Figure 4" Structure of GSH-Tc-GSH complex
Table II1" Biodistribution of 99mTc-GSH complex in normal sprague dawley rats (n 5)
organ %dose/g
h 6h
kidneys 17,5 + 3 19,7 + 3
urine 52 + 9 69 + 11
blood 5,3 + 0,6 2,3 + 0,23
liver 4,2 + 0,5 2,6 + 0,23
heart 2,5 + 2,3 2,3 + 0,23
spleen 2,17 + 0,15 2,2 + 0,15
lung 1,4 + 0,12 1,1 + 0,12
Figure 5 radiochromatogram of Tc-GSH complex obtained by biogel P2 chromatography
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Figure 6 Blood clearance of 99mTc-GSH complex in male sprague dawley rats (n 5)
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Figure 7 Biodistribution of 99mTc-GSH complex in normal sprague dawley rats (n 5)
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The blood clearance of 99mTc-GSH complex in rats is shown on (fig. 6). The deconvolution of
this curve demonstrated a rapid component (T1/2 (1) 50 min, T1/2 (2) 400 min).
The biodistribution of 99mTc-GSH complex is given in (table III). All organs slowed low uptake
values except kidneys. The elimination occured via the kidneys as indicated by high radioactivity
levels in urine samples (fig. 7).
DISCUSSION
In the present study, labeling of glutathione with 99mTc using stanous chloride as reducing
agent gave a dimer complex with a high radiochemical yield, over 95 % detected by thin layer
chromatography
The NMR spectrum of the Tc-GSH complex indicated that the protons bound to cysteinyl
o and 13 carbons appeared to be modified, suggesting an effect of the central Tc=O core in the
molecule.
Glutathione GSH could fulfill the fonction of a reducing agent and of a ligand for 99mTcO4".
The complexation rate seems to be higher than the reduction, since no ligand free Tc(V)
compound was formed. The reduction rate diminished by decreasing the concentration of the
GSH, which offers the possibility of determining the oxydation state in the complex by Sn(ll) titration
(20,21)
Some properties of the 99mTc-GSH complex have already been reported (18). A highly water-
soluble complex with a negative charge was formed. Blood clearance studies indicated a fast
decline of radioactivity during the first hour after administration.
According to Despopoulos theory (19), an agent could be secreted through the renal tubles
if it possesses anionic properties and bonding capability wich are expressed through the -CO-NH-
(CH2)-COOH sequence.The biodistribution of the anion 99mTc-GSH complex with the carbonyl
amide sequence showed that the target organ was the kidney with a fast elimination by filtration.
Glutathione plays a critical role in the detoxification reactions by reducing H202 (15,24). There is
increased demand for GSH in the injured and cancerous cells (23-26) and possible retention.
Although the thiol group responsible for such detoxification reactions was utilized for 99mTc binding
in the 99mTc-GSH complex (27,28). GSH might be still be biologically active.
99mTc-GSH complex is a small molecule which diffuses back from inflammatory and cancerous
lesions into the blood very easily (6,9,17).This intracellular concentration might be due to the
transfer of 99mTc to another ligand inside the cell allowing concentration.(29,30).
ACKNOWLEDGEMENTS
This work was supported by grants from the Cancer ligues dp:89 and 93. The authors thank
laboratoire de chimie, Y.Leroux, D. El Manouni and G. Leger for recording NMR spectra. F.
Benazzouz for helpful experiments and G.Baillet for paper reviewing
GSH glutathione, Tc technetium, SnCI2 stanous chloride, cys cysteine, gly glycine, glu
glutamic acid, TcO4: pertechnetate ion
REFERENCES
1) Jones A.G. and Davison A. Int. J. Appl. Radiat./sot. 1982; 33:867-874
2) Eclman W.C., Meinken G. and Richard P. J. Nucl. Med. 1972; 13:577-58
3) Tubis M., Endow J.S. Int. J. AppL Radiat. Isot. 1968; 19:835-840
4) Tubis M., Krishnamurthy G.T., Endow J.S. and Blahd W.H.J. Nucl. Med. 1972; 13:652-654
5) Lin T.H., Khentigan A., Winchell H.S.J. Nucl. Med. 1974; 15:34-35
6) Hagan P.I., Ayres P.R., Halpin S.E. and Chauncey D.M.J. Nucl. Med. 1975; 16:531-532
7) Inoue O., Ikeda I., Kuruta K. Radioisotopes. 1976; 25:23-30
8) Roizenblatt J., Buchpiguel C.A., Menguetti J.C., Caldeira J.A. and Camargo E.E. Eur. J. Nucl.
Med. 1991 18:955-95.8.
9) Ercan M.T., Aras T., Unlenen E., 0nlQ M., 0nsal I., Haselik Z. Nucl. Med. Biol. 1993; 20:881-887
10) Ercan M.T., Bekdik C.F., Sarizi T. Int. J. Appl. Radiol. Isot. 1978; 29:697-698
11) Fischman A.J., Pike M.C., Kroon D., Fucello A.C., Rexinger D., Tenkate C., Wilkinson R., Rubin
R.H. and Strauss H.W.J. Nucl. Med. 1991;32:483-991
12) Mankhetrkon S., Blanchot C., Duran-Cordobes M., EIManouni D., LerouxY. And Moretti J.L.
Metal Based Drug 1995; 2 (14):201-210
13) de Kieviet W. J. Nucl. Med. 1981;22:7.3-709
14) Hansen L, Marzilli L.G. and Taylor A. Q. J. Nucl. Med. 1998; 42:280-293
15) Kapiowitz N., Aw T.Y., Ookhtens M. Ann. Rev. Pharmacol. Toxicol. 1985; 25:715-744
335Vol. 6, No. 6, 1999 Tc-Glutathione Complex (Tc-GSH)." Labelling, Chemical
Characterization and Biodistribution in Rats
16) Hosain F., Haddon M.J., Hosain H., Drost J. and Spencer R.P. NucL Med. BioL 1990; 17:1 51-
155
17) Duman Y., Bilkay 0., Teber E., YQksel D., Erdem S., Argon M., Yilmaz R. and zbal O. Eur. J.
Nucl. Med. 1996; 19 1097-10
18) Ercan M.T., Aras T., Aktas T., 0nlenen E., Mocan G. and Bekdik R.P. Nucl. Med., 1994, 3 3
:224-228
19) Despopoulos A. J., J. Thero. Biol., 1965, 8 163-192
20) Person B.R.P.and Darte L. J. Chromatogr. 1974; 101:315-326
21) Steigman J., Meinken G., Richards P. Int. J. Appl. Radiat. Isot. 1975; 26:601-609
22) Ecklman W.C., Meinken G., Richards P. J. Nucl. Med. 1972; 13:577-581
23) Bernard B.F., Krenning E.P., Breeman W.AoP., Rolleman E.J., Bakker W.H., Visser T.J., M&kke
H. and de Jong M. J. Nucl. Med. 1997; 38:29-1933
24) Meister A., Anderson M.E. Ann.Rev. Biochem. 1983; 52:417-423
25) Reed D.J. Ann. Rev. Pharmacol. ToxicoL 1990, 30:603-631
26) Dalhoff K., Ranek L., Mantoni M. and Poulsen H.E. Liver.1992; 1:341-343
27) Suess E., Malessa K., UngersbSck, Kitz P., Podreka I., Heimberger K., Hornykiewicz O. and
Deecke L. J. Nucl. Med., 1991; 32:1675-1681
28) Muenze R. Technetium-99m radiopharmaceuticals structure-activity relationships. In Deckart
H, Cox PH eds. Principales of radiopharmacology. Dordrecht Martinus Nijhoff, 1987:100-116
29) Xue L.Y., Noujaim A.A., Sykes T.R., Woo T.R. and Peng Z. Q. J. Nucl. Med. 1996; 40:341-350
30) Syhre R., Seifert S., Spies H., Gupta A. and Johannsen B. Eur. J. Nucl. Med. 1998; 25:793-
796
Received: June 8, 1999 Accepted: June 25, 1999
Received in revised camera-ready format: August 23, 1999
336